Androgen receptor down-regulation in prostate cancer with phosphorodiamidate morpholino antisense oligomers

Journal of Urology

Volumn 172, Issue 3, 2004, Pages 1140-1144

  Ko, Yoo Joung ^a,c   Devi, Gayathri R ^b   London, Carla A ^b   Kayas, Anthony ^a   Reddy, Muralimohan T ^b   Iversen, Patrick L ^b   Bubley, Glenn J ^a   Balk, Steven P ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b AVI BIOPHARMA INC   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Androgen antagonists; Androgens; Oligonucleotides, antisense; Prostate; Prostatic neoplasms

Indexed keywords

ANDROGEN RECEPTOR; MESSENGER RNA; OLIGOMER; PHOSPHOROPDIAMIDATE MORPHOLINO ANTISENSE OLIGOMER; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CONTROLLED STUDY; DOSE RESPONSE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PLASMID; PRIORITY JOURNAL; PROSTATE; PROSTATE CANCER; RECEPTOR DOWN REGULATION; XENOGRAFT;

EID: 4143129940     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ju.0000134698.87862.e6     Document Type: Article

References (20)

1. Gelmann, E. P.: Molecular biology of the androgen receptor. J Clin Oncol, 20: 3001, 2002
2. Joyce, R., Fenton, M. A., Rode, P., Constantine, M., Gaynes, L., Kolvenbag, G. et al: High dose bicalutamide for androgen independent prostate cancer: effect of prior hormonal therapy. J Urol, 159: 149, 1998
3. Koivisto, P., Kononen, J., Palmberg, C., Tammela, T., Hyytinen, E., Isola, J. et al: Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res, 57: 314, 1997
4. Grossmann, M. E., Huang, H. and Tindall, D. J.: Androgen receptor signaling in androgen-refractory prostate cancer. J Natl Cancer Inst, 93: 1687, 2001
5. Taplin, M. E., Bubley, G. J., Ko, Y. J., Small, E. J., Upton, M., Rajeshkumar, B. et al: Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Res, 59: 2511, 1999
6. Gregory, C. W., He, B., Johnson, R. T., Ford, O. H., Mohler, J. L., French, F. S. et al: A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res, 61: 4315, 2001
7. Nazareth, L. V. and Weigel, N. L.: Activation of the human androgen receptor through a protein kinase A signaling pathway. J Biol Chem, 271: 19900, 1996
8. Craft, N., Shostak, Y., Carey, M. and Sawyers, C. L.: A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med, 5: 280, 1999
9. Zegarra-Moro, O. L., Schmidt, L. J., Huang, H. and Tindall, D. J.: Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells. Cancer Res, 62: 1008, 2002
10. Summerton, J.: Morpholino antisense oligomers: the case for an RNase H-independent structural type. Biochim Biophys Acta, 1489: 141, 1999
11. Devi, G. R., Oldenkamp, J. R., London, C. A. and Iversen, P. L.: Inhibition of human chorionic gonadotropin beta-subunit modulates the mitogenic effect of c-myc in human prostate cancer cells. Prostate, 53: 200, 2002
12. Knapp, D. C., Mata, J. E., Reddy, M. T., Devi, G. R. and Iversen, P. L.: Resistance to chemotherapeutic drugs overcome by c-Myc inhibition in a Lewis lung carcinoma murine model. Anticancer Drugs, 14: 39, 2003
13. Stanbrough, M., Leav, I., Kwan, P. W., Bubley, G. J. and Balk, S. P.: Prostatic intraepithelial neoplasia in mice expressing an androgen receptor transgene in prostate epithelium. Proc Natl Acad Sci USA, 98: 10823, 2001
14. Klein, K. A., Reiter, R. E., Redula, J., Moradi, H., Zhu, X. L., Brothman, A. R. et al: Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice. Nat Med, 3: 402, 1997
15. Dias, N. and Stein, C. A.: Antisense oligonucleotides: basic concepts and mechanisms. Mol Cancer Ther, 1: 347, 2002
16. Eder, I. E., Culig, Z., Ramoner, R., Thurnher, M., Putz, T., Nessler-Menardi, C. et al: Inhibition of LncaP prostate cancer cells by means of androgen receptor antisense oligonucleotides. Cancer Gene Ther, 7: 997, 2000
17. Eder, I. E., Hoffmann, J., Rogatsch, H., Schafer, G., Zopf, D., Bartsch, G. et al: Inhibition of LNCaP prostate tumor growth in vivo by an antisense oligonucleotide directed against the human androgen receptor. Cancer Gene Ther, 9: 117, 2002
18. Giles, R. V., Spiller, D. G., Clark, R. E. and Tidd, D. M.: Antisense morpholino oligonucleotide analog induces missplicing of C-myc mRNA. Antisense Nucleic Acid Drug Dev, 9: 213, 1999
19. Iversen, P. L., Arora, V., Acker, A. J., Mason, D. H. and Devi, G. R.: Efficacy of antisense morpholino oligomer targeted to c-myc in prostate cancer xenograft murine model and a Phase I safety study in humans. Clin Cancer Res, 9: 2510, 2003
20. Levin, A. A.: A review of the issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleotides. Biochim Biophys Acta, 1489: 69, 1999